Hiep T Tran
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$5.5MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
14 awards · $5.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Mar 31, 2025 | NIH | SBIR Phase II Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases | $826K | ABZYME THERAPEUTICS LLC |
| Feb 29, 2024 | NIH | SBIR Phase II Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases | $832K | ABZYME THERAPEUTICS LLC |
| May 22, 2023 | NIH | SBIR Phase I Novel immune-escape uricase for treatment of hyperuricemia | $300K | ABZYME THERAPEUTICS LLC |
| Sep 10, 2021 | NIH | SBIR Phase I Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis | $399K | ABZYME THERAPEUTICS LLC |
| Aug 13, 2019 | NIH | SBIR Phase I Pemphigus-specific T cell engagers for pemphigus targeted immunotherapy | $280K | ABZYME THERAPEUTICS LLC |
| Aug 23, 2018 | NIH | SBIR Phase II High throughput camelid antibody screening as a drug discovery platform | $170K | ABZYME THERAPEUTICS LLC |
| Sep 22, 2017 | NIH | SBIR Phase I Modular antibody engineering to overcome the blood brain barrier | $237K | ABZYME THERAPEUTICS LLC |
| Sep 14, 2017 | NIH | SBIR Phase I Development Of Arginine Linkage-Specific Antibodies | $225K | ABZYME THERAPEUTICS LLC |
| Aug 23, 2017 | NIH | SBIR Phase II High throughput camelid antibody screening as a drug discovery platform | $750K | ABZYME THERAPEUTICS LLC |
| Aug 24, 2016 | NIH | SBIR Phase II High throughput camelid antibody screening as a drug discovery platform | $750K | ABZYME THERAPEUTICS LLC |
| Mar 9, 2016 | NIH | SBIR Phase I Hybridoma-free multiplex approach for accelerating mouse monoclonal antibody generation | $40K | ABZYME THERAPEUTICS LLC |
| Jun 22, 2015 | NIH | SBIR Phase I High throughput approach for generating human monoclonal antibodies | $225K | ABZYME THERAPEUTICS LLC |
| Apr 30, 2015 | NIH | SBIR Phase I Hybridoma free multiplex approach for accelerating mouse monoclonal antibody generation | $225K | ABZYME THERAPEUTICS LLC |
| Feb 3, 2015 | NIH | SBIR Phase I Nanobodies for topical delivery to inhibit abnormal choroidal angiogenesis | $225K | ABZYME THERAPEUTICS LLC |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#231
Awards as PI#57
Patents#273
Companies
- ABZYME THERAPEUTICS LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.